Age-Related Macular Degeneration (AMD) Clinical Trial
Official title:
A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01694680 -
Intervention Trial in Early Age-related Macular Degeneration
|
N/A | |
| Completed |
NCT01224847 -
Intravitreal Injection Anesthesia - Comparison of Different Topical Agents
|
N/A | |
| Withdrawn |
NCT04697953 -
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
|
Phase 3 | |
| Completed |
NCT05037396 -
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
|
||
| Completed |
NCT00647439 -
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
|
||
| Terminated |
NCT00902785 -
A Study Of Early Markers Of Choroidal Neovascularization
|
Phase 4 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT03690505 -
Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
|
N/A | |
| Recruiting |
NCT03577041 -
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
|
||
| Completed |
NCT05082415 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
|
||
| Completed |
NCT02445313 -
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
|
||
| Completed |
NCT05111743 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
|
||
| Terminated |
NCT02398500 -
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT05146687 -
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
|
||
| Completed |
NCT05110209 -
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
|
||
| Not yet recruiting |
NCT05780931 -
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
|
||
| Recruiting |
NCT04292080 -
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
|
Phase 2 | |
| Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
| Completed |
NCT02022540 -
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
|
Phase 1 | |
| Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A |